Inflarx (IFRX) Research Coverage Started at J P Morgan Chase & Co
Equities researchers at J P Morgan Chase & Co initiated coverage on shares of Inflarx (NASDAQ:IFRX) in a research note issued to investors on Monday, MarketBeat reports. The brokerage set an “overweight” rating and a $30.00 price target on the stock. J P Morgan Chase & Co’s target price would indicate a potential upside of 55.93% from the company’s previous close.
Shares of Inflarx (IFRX) traded down $1.64 during trading on Monday, reaching $19.24. 48,357 shares of the company’s stock traded hands, compared to its average volume of 56,424. Inflarx has a 52 week low of $14.47 and a 52 week high of $22.48.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/04/inflarx-ifrx-research-coverage-started-at-j-p-morgan-chase-co.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx NV and related companies with MarketBeat.com's FREE daily email newsletter.